Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx And Bextra Get Split Votes From FDA Cmte. On Marketing

This article was originally published in The Pink Sheet Daily

Executive Summary

Vote slightly favors return of Vioxx to the market and continued marketing of Bextra. "Black box" warning on cardiovascular risk is recommended for COX-2s, including Pfizer's Celebrex. Restriction or banning of direct-to-consumer advertising also is advised by committee members.

You may also be interested in...



Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting

Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia

Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting

Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia

Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options

Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

PS061591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel